News Release

Two Research Articles Cite HemogloBind™ to Remove Analytical Interference from Hemoglobin

MONMOUTH JUNCTION, NJ, October 17, 2023 -- Biotech Support Group reports on two journal articles describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interferences prior to analysis.

The first citation is:

Kaneko, Tomonori, et al. "Kinome and phosphoproteome reprogramming underlies the aberrant immune responses in critically ill COVID-19 patients." (2023).

The SARS-CoV-2 infection elicits comprehensive host immune reactions and causes severe diseases in some individuals. However, the molecular basis underlying the excessive, yet non-productive immune responses in severe COVID-19 is not fully understood. To address this, we compared the peripheral blood mononuclear cell (PBMC) proteome and phosphoproteome of sepsis patients positive or negative for SARS-CoV-2 and healthy subjects by quantitative mass spectrometry. The article states “For Sample processing for proteomics by mass spectrometry,… Hemoglobin was depleted from PBMC whole cell lysate samples according to HemogloBind (Biotech Support Group LLC) manufacturer instruction …” The report shows that COVID-19 PBMC proteome and phosphoproteome undergo dynamic changes during disease progression, and the corresponding protein or phosphoprotein signatures can distinguish longitudinal disease states. Furthermore, SARS-CoV-2 infection leads to a global reprogramming of the kinome and the phosphoproteome, resulting in defective adaptive immune response mediated by B and T lymphocytes, compromised innate immune responses involving the SIGLEC and SLAM family of immunoreceptors, and excessive cytokine-JAK-STAT signaling.

The second citation is:

Dugbartey, George J., et al. "Static cold storage with mitochondria-targeted hydrogen sulfide donor improves renal graft function in an ex vivo porcine model of controlled donation-after-cardiac-death kidney transplantation." International Journal of Molecular Sciences 24.18 (2023): 14017.

The global donor kidney shortage crisis has necessitated the use of suboptimal kidneys from donors-after-cardiac-death (DCD). Using an ex vivo porcine model of DCD kidney transplantation, the present study investigates whether the addition of hydrogen sulfide donor, AP39, to University of Wisconsin (UW) solution improves graft quality. Urine and arterial blood samples were collected hourly during reperfusion. The article states “Urine protein levels were measured using an IDEXX Urine Analyzer (IDEXX Laboratories, Westbook, ME, USA) following a 1:3 dilution of urine in HemogloBind (Biotech Support Group, Monmouth Junction, NJ, USA) to obtain clearer urine samples after 10 min of vigorous shaking and centrifugation at 12,000× g.”. The observations indicate significant increases in urine production and blood flow rate, and reduced levels of urine protein, serum creatinine, blood urea nitrogen, plasma Na+ and K+ , as well as reduced intrarenal resistance in the UW+AP39 group compared to the UW-only group. Histologically, AP39 preserved renal structure by reducing the apoptosis of renal tubular cells and immune cell infiltration. The finding could lay the foundation for improved graft preservation and reduce the increasingly poor outcomes associated with DCD kidney transplantation.

“All of our products are species agnostic, as they not derived from immuno-affinity, so they work for all species to the best of our knowledge. Here are two examples of this, one in human, and one in pig, whereby HemogloBind™ improves the analysis by removing Hemoglobin as an interfering component.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, COVID-19, SARS-CoV-2, mass spectrometry, tandem mass tag, kinome reprogramming, immune regulation, donation-after-cardiac-death (DCD); ex vivo porcine model; AP39; hydrogen sulfide (H2S); ischemia-reperfusion injury (IRI); kidney transplantation

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com